Compare · AKTX vs LLY
AKTX vs LLY
Side-by-side comparison of Akari Therapeutics plc (AKTX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKTX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 57618.1x AKTX ($19.3M).
- Over the past year, AKTX is down 74.7% and LLY is up 52.7% - LLY leads by 127.4 points.
- AKTX has been more active in the news (13 items in the past 4 weeks vs 11 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 3 for AKTX).
- Company
- Akari Therapeutics plc
- Eli Lilly and Company
- Price
- $11.24-7.34%
- $1178.57+0.73%
- Market cap
- $19.3M
- $1.11T
- 1M return
- -18.25%
- +5.00%
- 1Y return
- -74.68%
- +52.71%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 13
- 11
- Recent ratings
- 3
- 25
Akari Therapeutics plc
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest AKTX
- Director Patel Samir Rashmikant exercised 22,474 units of American Depositary Shares representing Ordinary Shares at a strike of $0.43 (SEC Form 4)
- SEC Form EFFECT filed by Akari Therapeutics plc
- Amendment: SEC Form S-3/A filed by Akari Therapeutics plc
- Amendment: SEC Form S-3/A filed by Akari Therapeutics plc
- SEC Form EFFECT filed by Akari Therapeutics plc
- Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
- Akari Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form S-3 filed by Akari Therapeutics plc
- Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
- SEC Form 8-K filed by Akari Therapeutics plc
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend